These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 14618097)

  • 1. Pharmacological modulation of cardiovascular remodeling: a guide to heart failure therapy.
    Remme WJ
    Cardiovasc Drugs Ther; 2003 Jul; 17(4):349-60. PubMed ID: 14618097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the relationship between ischemia and congestive heart failure.
    Remme WJ
    Clin Cardiol; 2000 Jul; 23(7 Suppl 4):IV4-8. PubMed ID: 10894449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implication of cardiac remodeling in heart failure: mechanisms and therapeutic strategies.
    Takano H; Hasegawa H; Nagai T; Komuro I
    Intern Med; 2003 Jun; 42(6):465-9. PubMed ID: 12857042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of ventricular remodeling in heart failure clinical trials.
    Kirkpatrick JN; St John Sutton M
    Curr Heart Fail Rep; 2012 Dec; 9(4):328-36. PubMed ID: 22983907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients.
    Orea-Tejeda A; Colín-Ramírez E; Castillo-Martínez L; Asensio-Lafuente E; Corzo-León D; González-Toledo R; Rebollar-González V; Narváez-David R; Dorantes-García J
    Rev Invest Clin; 2007; 59(2):103-7. PubMed ID: 17633796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical algorithms for pharmacologic management of the post myocardial infarction patient.
    Reiffel JA; ;
    Clin Cardiol; 2005 Nov; 28(11 Suppl 1):I28-37. PubMed ID: 16450810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurohumoral activation and progression of heart failure: hypothetical and clinical considerations.
    Francis GS
    J Cardiovasc Pharmacol; 1998; 32 Suppl 1():S16-21. PubMed ID: 9731691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular dilatation after myocardial infarction: ACE inhibitors, beta-blockers, or both?
    Anthonio RL; van Veldhuisen DJ; van Gilst WH
    J Cardiovasc Pharmacol; 1998; 32 Suppl 1():S1-8. PubMed ID: 9731689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first?
    Remme WJ
    Cardiol Clin; 2007 Nov; 25(4):581-94; vii. PubMed ID: 18063162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of left ventricular remodelling after acute myocardial infarction: an update.
    Rossini R; Senni M; Musumeci G; Ferrazzi P; Gavazzi A
    Recent Pat Cardiovasc Drug Discov; 2010 Nov; 5(3):196-207. PubMed ID: 20874671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs for left ventricular remodeling in heart failure.
    Frigerio M; Roubina E
    Am J Cardiol; 2005 Dec; 96(12A):10L-18L. PubMed ID: 16399088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis and pathophysiology of heart failure with reduced ejection fraction: translation to human studies.
    Ge Z; Li A; McNamara J; Dos Remedios C; Lal S
    Heart Fail Rev; 2019 Sep; 24(5):743-758. PubMed ID: 31209771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ACE-inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure.
    Khattar RS
    Minerva Cardioangiol; 2003 Apr; 51(2):143-54. PubMed ID: 12783070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.
    Fraccarollo D; Galuppo P; Schmidt I; Ertl G; Bauersachs J
    Cardiovasc Res; 2005 Jul; 67(1):97-105. PubMed ID: 15949473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurohormonal modulation in heart failure: ACE inhibition and beyond.
    Remme WJ
    Eur Heart J; 1995 Dec; 16 Suppl N():73-8. PubMed ID: 8682065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
    Fraccarollo D; Galuppo P; Motschenbacher S; Ruetten H; Schäfer A; Bauersachs J
    Basic Res Cardiol; 2014 Jul; 109(4):421. PubMed ID: 24907870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More hope for heart failure. Findings suggest expanded use of aldosterone-blockers.
    Aaronson K
    Health News; 2003 May; 9(5):4. PubMed ID: 12739453
    [No Abstract]   [Full Text] [Related]  

  • 19. Mineralocorticoid receptor antagonism and cardiac remodeling in ischemic heart failure.
    Fraccarollo D; Galuppo P; Bauersachs J
    Curr Med Chem Cardiovasc Hematol Agents; 2004 Oct; 2(4):287-94. PubMed ID: 15320779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U; Wollert KC; Drexler H
    Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.